Riskpilot← Back to searchSign inGet full accessBarbos Läkarkonsult AB
ABActiveOrg 5593649832Ljungaskog 208General medical practice activities · NACE 8621Est. 20220 employees
Revenue 2024
SEK 857K
+94% vs 2023
EBITDA margin
52.0%
+14% vs 2023
Equity ratio
65.5%
Financial strength
Net profit 2024
SEK 357K
+16% vs 2023
| Revenue | SEK 857K | +94% |
| EBITDA | SEK 446K | +14% |
| Net profit | SEK 357K | +16% |
| Total assets | SEK 745K | +46% |
| Equity | SEK 488K | +47% |
| Employees | 0 | — |
Legal name
Barbos Läkarkonsult AB
Org number
5593649832
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
10 februari 2022
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva medicinsk verksamhet (forskning, utbildning och konsultationer) inom hälso- och skönhetsvård. Import och export av medicinsk utrustning. Handel och förvaltning av värdepapper samt fast och lös egendom.
Address
Ljungaskog 208
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 441 | 857 |
| Staff expenses | — | −0 | — | — |
| EBITDA | −1 | −1 | 390 | 446 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | −1 | −1 | 390 | 446 |
| Net financials | — | 0 | — | −1 |
| Profit before tax | −1 | −1 | 390 | 446 |
| Tax | −0 | −0 | −83 | −89 |
| Net profit | −1 | −1 | 307 | 357 |
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 24 | 24 | 511 | 745 |
| Equity | 24 | 24 | 331 | 488 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 180 | 257 |
| Total debt | — | 0 | 180 | 257 |
EBITDA margin
52.0%
This company
15.8%
Market median
+229% vs market
20222024
Equity ratio
65.5%
This company
38.2%
Market median
+71% vs market
20222024
Return on equity
73.2%
This company
18.4%
Market median
+298% vs market
20222024
Net profit margin
41.7%
This company
8.1%
Market median
+415% vs market
20222024
Asset turnover
1.15×
This company
1.12×
Market median
+3% vs market
20222024
Debt / equity
0.53×
This company
0.62×
Market median
+15% vs market
20222024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-02-10 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-02-01 – 2022-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AC Chief Executive Officer | Chief Executive Officer | 2022 |
GL | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Barbos Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andrei Codrut Barbos | Chief Executive Officer | 0 companies |
| Gösta Lars-Olof Pettersson | Audit | 0 companies |
| Timotei-Ionel Barbos | Deputy Board Member | 0 companies |